Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.

Abstract: In one embodiment, a method includes accessing, from a data store of the communication network, user information associated with a first user of the communication network, identifying one or more entities associated with the communication network that are relevant to the first user based on the user information, and retrieving, for each identified entity, one or more content frames associated with the entity. The method includes ranking the one or more content frames based on the user information. The method also includes sending, to a client device of the first user, one or more of the content frames for display to the first user in ranked order, wherein each content frame is selectable by the first user to display the selected content frame in association with a particular content item for a specified period of time.

Abstract: The present application provides a low load operating system for a refrigeration system having a compressor, a condenser, an expansion valve, and an evaporator. The low load operating system may include a hot gas bypass line extending from a discharge side of the compressor to a suction side of the compressor and a desuperheat line extending from upstream of the expansion valve to the suction side of the compressor.

Abstract: The present application provides a low load operating system for a refrigeration system having a compressor, a condenser, an expansion valve, and an evaporator. The low load operating system may include a hot gas bypass line extending from a discharge side of the compressor to a suction side of the compressor and a desuperheat line extending from upstream of the expansion valve to the suction side of the compressor.

Abstract: Described herein are methods and systems for identifying and/or treating subjects having cancer who are more likely to respond to treatment with an inhibitor of the transcription factor HIF-2?.

Abstract: The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of ?-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.

Abstract: In one embodiment, a method includes accessing, from a data store of the communication network, user information associated with a first user of the communication network, identifying one or more entities associated with the communication network that are relevant to the first user based on the user information, and retrieving, for each identified entity, one or more content frames associated with the entity. The method includes ranking the one or more content frames based on the user information. The method also includes sending, to a client device of the first user, one or more of the content frames for display to the first user in ranked order, wherein each content frame is selectable by the first user to display the selected content frame in association with a particular content item for a specified period of time.

Abstract: The present application provides a low load operating system for a refrigeration system having a compressor, a condenser, an expansion valve, and an evaporator. The low load operating system may include a hot gas bypass line extending from a discharge side of the compressor to a suction side of the compressor and a desuperheat line extending from upstream of the expansion valve to the suction side of the compressor.

Abstract: The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of ?-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.

Abstract: A radiation-hardened memory storage unit that is resistant to total ionizing done effects, the unit including PMOS transistors.

Abstract: A radiation-hardened storage unit, including a basic storage unit, a redundant storage unit, and a two-way feedback unit. The basic storage unit includes a first PMOS transistor, a second PMOS transistor, a third PMOS transistor, and a fourth PMOS transistor. The first PMOS transistor and the second PMOS transistor are read-out access transistors. The third PMOS transistor and the fourth PMOS transistor are write-in access transistors. The redundant storage unit includes a fifth PMOS transistor, a sixth PMOS transistor, a seventh PMOS transistor, and an eighth PMOS transistor. The fifth PMOS transistor and the sixth PMOS transistor are read-out access transistors. The seventh PMOS transistor and the eighth PMOS transistor are write-in access transistors. The two-way feedback unit is configured to form a feedback path between the storage node and the redundant storage node.

Abstract: A radiation-hardened memory storage unit that is resistant to total ionizing done effects, the unit including PMOS transistors.

Abstract: A radiation-hardened storage unit, including a basic storage unit, a redundant storage unit, and a two-way feedback unit. The basic storage unit includes a first PMOS transistor, a second PMOS transistor, a third PMOS transistor, and a fourth PMOS transistor. The first PMOS transistor and the second PMOS transistor are read-out access transistors. The third PMOS transistor and the fourth PMOS transistor are write-in access transistors. The redundant storage unit includes a fifth PMOS transistor, a sixth PMOS transistor, a seventh PMOS transistor, and an eighth PMOS transistor. The fifth PMOS transistor and the sixth PMOS transistor are read-out access transistors. The seventh PMOS transistor and the eighth PMOS transistor are write-in access transistors. The two-way feedback unit is configured to form a feedback path between the storage node and the redundant storage node.

Abstract: The present invention is drawn to methods of predicting prognosis of, and therapeutic response in, carcinoma of the lung.

Abstract: The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of ?-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.